New Zealand markets closed

Takeda Pharmaceutical Company Limited (TAK)

NYSE - NYSE Delayed price. Currency in USD
Add to watchlist
14.77-0.07 (-0.47%)
At close: 04:00PM EDT
15.00 +0.23 (+1.56%)
After hours: 06:50PM EDT
Show:
Annual

Income statement

Currency in JPY. All numbers in thousands
Breakdown
ttm
31/03/2022
31/03/2021
31/03/2020
31/03/2019
Total revenue
3,569,006,000
3,569,006,000
3,197,812,000
3,291,188,000
2,097,224,000
Cost of revenue
1,106,846,000
1,106,846,000
994,308,000
1,089,764,000
659,690,000
Gross profit
2,462,160,000
2,462,160,000
2,203,504,000
2,201,424,000
1,437,534,000
Operating expenses
Research development
526,087,000
526,087,000
455,833,000
492,381,000
368,298,000
Selling general and administrative
886,361,000
886,361,000
875,663,000
964,737,000
717,599,000
Total operating expenses
2,001,315,000
2,001,315,000
1,865,193,000
1,926,716,000
1,277,169,000
Operating income or loss
460,845,000
460,845,000
338,311,000
274,708,000
160,365,000
Interest expense
166,607,000
166,607,000
130,806,000
149,010,000
48,158,000
Total other income/expenses net
-15,367,000
-15,367,000
165,770,000
-188,813,000
-4,510,000
Income before tax
302,571,000
302,571,000
366,235,000
-60,754,000
94,896,000
Income tax expense
72,405,000
72,405,000
-9,936,000
-105,044,000
-14,118,000
Income from continuing operations
230,166,000
230,166,000
376,171,000
44,290,000
109,014,000
Net income
230,059,000
230,059,000
376,005,000
44,241,000
109,126,000
Net income available to common shareholders
230,059,000
230,059,000
376,005,000
44,241,000
109,126,000
Basic EPS
-
-
120.36
14.21
56.75
Diluted EPS
-
-
119.48
14.12
56.43
Basic average shares
-
-
3,124,012
3,114,408
1,922,954
Diluted average shares
-
-
3,147,074
3,132,408
1,933,794
EBITDA
-
1,052,329,000
1,056,712,000
671,905,000
415,500,000